With this agreement, consumers will see new 1.5g single-use sachets of the rapidly growing LivRelief Pain Relief Cream, LivRelief Nerve Pain Cream and LivRelief Healing Cream available in convenience stores throughout Canada. This will add to the LivRelief successful brand awareness strategy for both its natural and pharmaceutical products.
“Spike offers unparalleled access to the Canadian market, providing comprehensive and consistently outstanding service to more than 27,000 points of sale from Vancouver Island to Newfoundland. This expanded availability and distribution, give consumers a new way to sample our products,” commented Dr. Joseph Gabriele, Delivra’s Chief Executive Officer. In addition, this revolutionary packaging system will be used for Delivra’s future pharmaceutical products to prevent overdosing. Delivra aims to increase brand awareness and drive sales of its larger sized products currently available in pharmacies and retail chains across the country. “
Delivra’s suite of topical creams under the “LivRelief” brand has been available in retail stores since 2012. The new, convenient single-use packages will begin to make their way into point of purchase displays. The 25-pack displays will make their way into as many as 500 retail locations in Canada, beginning February, 2017. The patented Easysnap packaging provides hygienic, clean ease of use for added convenience. Delivra’s suite of products utilizes the transdermal delivery technology developed by Dr. Joseph Gabriele and his team at Delivra. Delivra uses the innovative transdermal delivery system to deliver target relief using natural ingredients. LivRelief products provide targeted opioid-free pain relief alternatives to millions of Canadians.
ABOUT DELIVRA CORP.
Delivra Corp. is a specialty biotechnology company that has a proprietary transdermal delivery system platform that can shuttle pharmaceutical and natural molecules, through the skin, in a targeted specific manner. Delivra manufactures and sells a growing line of natural topical creams with the proprietary transdermal delivery system platform under the LivReliefTM brand, for conditions such as joint and muscle pain, nerve pain, varicose veins, wound healing, and under the LivSportTM brand for sports performance. LivReliefTM products are available in pharmacies, grocery chains, and independent health food stores across Canada, and on-line at livrelief.com. LivReliefTM pain and nerve pain products are also available in the United States on Amazon and at www.livrelief.com/us. In parallel with its consumer products business, Delivra also has a mandate to license its patent-pending proprietary transdermal delivery technology platform to pharmaceutical companies globally, for the transdermal delivery of repurposing Rx molecules to treat a broad range of conditions, along with licensing its over-the-counter products globally. Delivra is headquartered in Burlington, Ontario and has a research and development laboratory in Charlottetown, PEI.
The TSX Venture Exchange has neither approved nor disapproved the contents of this press release. Neither the Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release. Certain information in this press release may constitute forward-looking information. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict. Actual results might differ materially from results suggested in any forward-looking statements. The Corporation assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward looking-statements unless and until required by securities laws applicable to the Corporation. Additional information identifying risks and uncertainties is contained in the Corporation’s filings with the Canadian securities regulators, which filings are available at www.sedar.com.
For more information, please contact: